Clinical Trial Results: Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of coformulated pembrolizumab/quavonlimab with lenvatinib in advanced hepatocellular carcinoma; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• pembrolizumab/quavonlimab (MK-1308A) coformulation (pembrolizumab/quavonlimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-06-23